JFS Wealth Advisors LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

JFS Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.1% in the third quarter, HoldingsChannel reports. The firm owned 269 shares of the medical research company’s stock after acquiring an additional 81 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $166,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Mission Wealth Management LP increased its holdings in Thermo Fisher Scientific by 8.6% in the first quarter. Mission Wealth Management LP now owns 4,326 shares of the medical research company’s stock valued at $2,514,000 after buying an additional 342 shares during the last quarter. Avior Wealth Management LLC raised its position in Thermo Fisher Scientific by 7.9% in the 1st quarter. Avior Wealth Management LLC now owns 4,251 shares of the medical research company’s stock valued at $2,471,000 after purchasing an additional 313 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Thermo Fisher Scientific by 2.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,668 shares of the medical research company’s stock worth $49,366,000 after purchasing an additional 1,754 shares during the period. 1834 Investment Advisors Co. raised its holdings in shares of Thermo Fisher Scientific by 10.0% in the first quarter. 1834 Investment Advisors Co. now owns 1,809 shares of the medical research company’s stock valued at $1,051,000 after buying an additional 164 shares during the last quarter. Finally, Connecticut Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 1.1% during the first quarter. Connecticut Wealth Management LLC now owns 4,842 shares of the medical research company’s stock worth $2,814,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.7 %

TMO stock opened at $546.55 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a 12 month low of $433.15 and a 12 month high of $627.88. The firm has a market capitalization of $208.78 billion, a PE ratio of 34.27, a P/E/G ratio of 3.64 and a beta of 0.77. The company’s 50 day simple moving average is $600.36 and its 200-day simple moving average is $583.31.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter last year, the business posted $5.69 earnings per share. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Stephens initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Barclays lowered their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,300 shares of company stock valued at $6,831,268. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.